Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole Safety in Elderly MDD
NCT02400346Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Mar 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD), sponsored by Lundbeck. Started Mar 2015; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02400346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02400346.